Acceleron Pharma Inc (NASDAQ:XLRN) CFO Kevin F. Mclaughlin sold 19,000 shares of the business’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $42.89, for a total transaction of $814,910.00. Following the sale, the chief financial officer now owns 45,300 shares in the company, valued at approximately $1,942,917. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Acceleron Pharma Inc (NASDAQ XLRN) opened at $42.11 on Friday. Acceleron Pharma Inc has a 52-week low of $23.07 and a 52-week high of $44.80. The firm has a market capitalization of $1,942.39, a PE ratio of -16.26 and a beta of 1.59.
Acceleron Pharma (NASDAQ:XLRN) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.02. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The business had revenue of $3.00 million during the quarter, compared to analyst estimates of $3.52 million. During the same quarter in the previous year, the firm earned ($0.55) EPS. Acceleron Pharma’s revenue was up .0% on a year-over-year basis. analysts anticipate that Acceleron Pharma Inc will post -2.65 earnings per share for the current year.
A number of brokerages have recently commented on XLRN. HC Wainwright restated a “buy” rating and set a $62.00 target price on shares of Acceleron Pharma in a report on Monday, December 11th. Oppenheimer reaffirmed a “hold” rating on shares of Acceleron Pharma in a research report on Wednesday, September 20th. BidaskClub raised Acceleron Pharma from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Royal Bank of Canada reaffirmed a “hold” rating on shares of Acceleron Pharma in a research report on Thursday, November 2nd. Finally, Credit Suisse Group set a $51.00 price target on Acceleron Pharma and gave the stock a “buy” rating in a research report on Tuesday, November 14th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $44.56.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.